Publications by authors named "A Ogimoto"
Article Synopsis
- Mavacamten, a cardiac myosin inhibitor, showed significant improvements in symptoms and heart function in Japanese patients with obstructive hypertrophic cardiomyopathy (HCM) during the HORIZON-HCM study.
- In a trial involving 38 patients, 36 completed the 30-week treatment, which resulted in a notable reduction in postexercise left ventricular outflow tract (LVOT) gradient and improvements in cardiac biomarkers and quality of life metrics.
- The treatment was well tolerated, with adverse events reported but none leading to discontinuation, and no deaths occurred throughout the study.
Article Synopsis
- - The study aimed to distinguish elderly aortic stenosis (AS) patients aged 70 and above based on the presence or absence of cardiovascular complications (CCs), enrolling a total of 156 patients.
- - Patients were categorized into two groups: group I (AS without CCs) and group II (AS with CCs), where significant differences were found in left ventricular hypertrophy, peak and mean transvalvular pressure gradients (TPGs), and brain natriuretic peptide (BNP) levels.
- - The findings indicated that BNP levels and the BNP/peak TPG ratio were effective markers for differentiating between AS patients with and without CCs, highlighting their potential clinical significance.
HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK-rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK-rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective.
View Article and Find Full Text PDF